Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25.03 | 26.32 | 32.03 | 27.47 | 30.41 | 31.13 | 31.32 | 28.61 | 34.84 | 32.96 | 34.74 | 33.19 |
| Expenses | 24.49 | 25.31 | 26.58 | 26.67 | 24.88 | 32.32 | 41.46 | 32.80 | 39.79 | 34.47 | 41.84 | 37.02 |
| Operating Profit | 0.54 | 1.01 | 5.45 | 0.80 | 5.53 | -1.19 | -10.14 | -4.19 | -4.95 | -1.51 | -7.10 | -3.83 |
| OPM % | 2.16% | 3.84% | 17.02% | 2.91% | 18.18% | -3.82% | -32.38% | -14.65% | -14.21% | -4.58% | -20.44% | -11.54% |
| Other Income | 0.77 | 0.23 | -0.86 | 0.22 | 0.64 | 0.23 | 0.73 | 9.47 | 1.70 | 1.13 | 1.91 | 0.26 |
| Interest | 0.65 | 0.61 | 3.26 | 0.46 | 0.72 | 0.43 | 2.48 | 0.82 | 2.58 | 2.84 | 1.10 | 2.79 |
| Depreciation | 0.32 | 0.34 | 1.15 | 0.36 | 1.98 | 0.72 | 1.92 | 1.65 | 0.99 | 1.15 | 1.69 | 1.87 |
| Profit before tax | 0.34 | 0.29 | 0.18 | 0.20 | 3.47 | -2.11 | -13.81 | 2.81 | -6.82 | -4.37 | -7.98 | -8.23 |
| Tax % | 100.00% | 368.97% | -194.44% | -125.00% | -4.90% | 27.96% | 11.30% | 27.76% | -6.74% | 5.26% | -7.39% | -1.82% |
| Net Profit | 0.00 | -0.79 | 0.53 | 0.46 | 3.65 | -2.70 | -15.38 | 2.03 | -6.36 | -4.60 | -7.39 | -8.08 |
| EPS in Rs | -0.12 | -0.90 | 0.22 | 0.27 | 2.84 | -2.40 | -12.92 | 1.65 | -5.26 | -3.69 | -5.97 | -6.14 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 46 | 50 | 59 | 59 | 77 | 62 | 80 | 93 | 108 | 126 | 131 | 136 |
| Expenses | 38 | 43 | 51 | 54 | 69 | 61 | 71 | 91 | 100 | 131 | 149 | 153 |
| Operating Profit | 8 | 7 | 8 | 5 | 7 | 1 | 10 | 3 | 9 | -5 | -18 | -17 |
| OPM % | 16% | 14% | 14% | 9% | 10% | 1.4% | 12% | 2.8% | 8% | -4.0% | -14% | -13% |
| Other Income | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 0 | 2 | 14 | 5 |
| Interest | 2 | 1 | 2 | 3 | 2 | 6 | 7 | 5 | 6 | 4 | 7 | 9 |
| Depreciation | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 5 | 6 |
| Profit before tax | 4 | 4 | 4 | 3 | 5 | -7 | 3 | -1 | 1 | -12 | -16 | -27 |
| Tax % | 33% | 22% | 31% | 19% | 11% | -28% | 15% | -23% | 185% | 14% | -0% | |
| Net Profit | 3 | 3 | 3 | 3 | 4 | -5 | 2 | -0 | -1 | -14 | -16 | -26 |
| EPS in Rs | 2.56 | 2.90 | 2.66 | 2.31 | 3.69 | -4.59 | 2.24 | -0.85 | -0.47 | -11.60 | -12.74 | -21.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 11% | 16% | 12% | 12% | ||
| Compounded Profit Growth | % | % | % | -104% | ||
| Stock Price CAGR | 8% | 19% | 2% | -67% | ||
| Return on Equity | -36% | -69% | -85% | -161% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 12 | 12 | 13 |
| Reserves | -19 | -17 | -4 | -3 | -7 | -3 | -7 | -4 | -5 | 7 | -3 | -2 |
| Borrowings | 70 | 69 | 56 | 75 | 62 | 64 | 77 | 70 | 72 | 76 | 71 | 86 |
| Other Liabilities | 11 | 11 | 17 | 20 | 27 | 31 | 34 | 34 | 37 | 38 | 49 | 41 |
| Total Liabilities | 73 | 73 | 81 | 103 | 92 | 103 | 114 | 110 | 115 | 133 | 129 | 138 |
| Fixed Assets | 33 | 34 | 34 | 32 | 33 | 33 | 33 | 44 | 46 | 41 | 47 | 50 |
| CWIP | 0 | 0 | 6 | 11 | 12 | 14 | 14 | 4 | 7 | 7 | 9 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 40 | 39 | 41 | 59 | 47 | 56 | 68 | 62 | 61 | 85 | 73 | 81 |
| Total Assets | 73 | 73 | 81 | 103 | 92 | 103 | 114 | 110 | 115 | 133 | 129 | 138 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | 6 | 4 | -10 | 12 | 5 | 7 | -0 | 10 | -1 | 5 | -24 |
| Cash from Investing Activity | -0 | -3 | -3 | -3 | -3 | -4 | -1 | -2 | -7 | -0 | -15 | -5 |
| Cash from Financing Activity | 2 | -2 | 0 | 17 | -12 | 1 | 6 | -13 | -2 | 20 | -9 | 32 |
| Net Cash Flow | 2 | -0 | 1 | 4 | -2 | 2 | 12 | -16 | 0 | 18 | -19 | 3 |
| Free Cash Flow | -0 | 2 | 3 | -16 | 10 | 2 | 6 | -3 | 4 | -2 | -8 | -30 |
| CFO/OP | 8% | 73% | 62% | -120% | 251% | 71% | 885% | -5% | 390% | 1% | -138% | 136% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 33 | 35 | 34 | 43 | 51 | 61 | 61 | 51 | 59 | 56 | 38 |
| Inventory Days | 287 | 227 | 319 | 338 | 311 | 313 | 268 | 254 | 227 | 205 | 208 | 200 |
| Days Payable | 150 | 100 | 112 | 125 | 117 | 162 | 149 | 168 | 137 | 114 | 93 | 129 |
| Cash Conversion Cycle | 172 | 160 | 242 | 247 | 236 | 202 | 179 | 147 | 141 | 149 | 171 | 109 |
| Working Capital Days | -131 | -103 | -213 | -63 | -24 | -19 | -99 | -118 | -81 | -172 | -147 | -162 |
| ROCE % | 8% | 9% | 9% | 9% | 6% | 9% | -0% | 11% | 2% | 8% | -9% | -10% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 61.52% | 63.44% | 58.58% | 58.58% | 58.58% | 58.58% | 58.58% | 37.83% | 33.14% | 33.14% | 35.60% | 35.60% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.22% | 0.17% | 0.17% |
| DIIs | 0.05% | 0.05% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% |
| Public | 38.43% | 36.51% | 41.37% | 41.39% | 41.38% | 41.37% | 41.37% | 62.12% | 66.81% | 66.59% | 64.20% | 64.18% |
| No. of Shareholders | 7,855 | 8,428 | 8,581 | 8,655 | 9,052 | 9,009 | 9,074 | 9,401 | 9,938 | 9,952 | 10,225 | 10,372 |
Fundamentals
Market Cap₹ 192 Cr.
Current Price₹ 148
Book Value₹ 8.56
ROCE-9.77 %
ROE-161 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)12%
Compounded Profit Growth (TTM)-104%
Consolidated figures.
Valuation
Market capRs 191 Cr
Enterprise valueRs 272 Cr
Price to book17.17x
Price to sales1.41x
EV / sales2.00x
Earnings yield-13.89%
P/B, 3-year average30.69x
P/E, 5-year average34.95x
P/B, 5-year average22.66x
Profitability
Operating margin (excl. other income)-13.53%
Operating margin (incl. other income)-2.70%
EBITDA margin-9.13%
Pre-tax margin-20.19%
Net profit margin-19.55%
Net margin, latest quarter-24.04%
ROE-160.70%
ROCE-10.16%
ROA-12.40%
ROE, 3-year average-88.18%
ROCE, 3-year average-3.91%
ROA, 3-year average-7.84%
ROE, 5-year average-46.07%
ROCE, 5-year average1.29%
ROA, 5-year average-4.44%
ROIC (approx.)-19.65%
Tax rate0.24%
Other income / net worth127.79%
Growth
Sales growth (latest year)4.42%
Sales CAGR, 3 years11.98%
Sales CAGR, 5 years16.14%
Sales growth QoQ-4.46%
Sales growth YoY (latest quarter)16.01%
Profit growth YoY (latest quarter)-501.00%
Per share
EPS (TTM)Rs -20.42
EPS (latest quarter)Rs -6.14
EPS, 3-year averageRs -6.03
EPS, 5-year averageRs -2.67
Book value per shareRs 8.56
Sales per shareRs 104.45
Cash flow per shareRs -18.57
Free cash flow per shareRs -23.09
Efficiency
Asset turnover0.95x
Fixed asset turnover2.62x
Inventory turnover1.83x
Inventory days200 days
Debtor days38 days
Debtors turnover9.50x
Creditor days129 days
Cash conversion cycle109 days
Working capital days-162 days
Leverage
Total debtRs 86 Cr
Cash and bankRs 6 Cr
Net debtRs 81 Cr
Debt to equity7.78x
Interest coverage-1.94x
Owners' fund to total sources8.03%
Debt to assets62.47%
Cash flow
Cash from Operating Activity (latest year)Rs -24 Cr
Cash from Investing Activity (latest year)Rs -5 Cr
Cash from Financing Activity (latest year)Rs 32 Cr
Net Cash Flow (latest year)Rs 3 Cr
Free cash flow (latest year)Rs -30 Cr
FCFE (approx.: FCF + change in debt)Rs -14 Cr
Statement figures
Net sales (TTM)Rs 136 Cr
Net sales (latest year)Rs 131 Cr
Sales (latest quarter)Rs 33 Cr
Operating profit excl. other income (latest year)Rs -18 Cr
Operating profit (latest quarter)Rs -4 Cr
Other income (TTM)Rs 5 Cr
EBITDA (TTM)Rs -12 Cr
PBDT (TTM)Rs -22 Cr
Profit before tax (TTM)Rs -27 Cr
Tax (latest year)Rs -0 Cr
Net profit (TTM)Rs -27 Cr
Net profit (latest year)Rs -17 Cr
Net profit (latest quarter)Rs -8 Cr
Depreciation (TTM)Rs 6 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 9 Cr
Cost of goods sold (latest year)Rs 28 Cr
Total expenditure (latest year)Rs 149 Cr
Total income (latest year)Rs 145 Cr
Share capitalRs 13 Cr
ReservesRs -2 Cr
Shareholders' fundsRs 11 Cr
Total assetsRs 138 Cr
Net blockRs 50 Cr
Capital work in progressRs 8 Cr
InvestmentsRs 0 Cr
ReceivablesRs 14 Cr
InventoryRs 15 Cr
Other liabilitiesRs 41 Cr
Shares outstanding (crore)1.30
Ownership
Promoter holding35.60% (-2.23 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 15.90 is at the 40th percentile (median 17.33).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 530163 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -11.6% | -2.8% | -8.8 pts |
| 1 month | -17.7% | -6.8% | -10.9 pts |
| 3 months | -20.6% | -7.6% | -12.9 pts |
| 3 years | +6.4% | +14.2% | -7.8 pts |
| 5 years | +142.1% | +27.9% | +114.2 pts |
Red flags
F-score 0 of 8| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹33 Cr +16.0% vs Jun 2025.
Net loss ₹8 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Kerala Ayurveda Ltd?
Kerala Ayurveda Ltd (530163) has a market capitalisation of Rs 192 Cr. at the 2026-10-01 close.
What were Kerala Ayurveda Ltd's latest quarterly results?
In the Jun 2026 quarter, Kerala Ayurveda Ltd sales was Rs 33 Cr (+16.0% vs Jun 2025) with a net loss of Rs 8 Cr.